Evaluating Simvastatin's Potential Role in Therapy

Completed · Phase 2 · Has a placebo group

Conditions studied: Alzheimer Disease

In brief

The purpose of this study is to see how simvastatin, a cholesterol-lowering drug, affects processes related to the development of Alzheimer's disease, including: 1) levels of a substance called beta-amyloid-42 found in the spinal fluid surrounding the brain, 2) blood flow in the brain, 3) inflammation in the brain, and 4) cognitive function.

Key facts

Study ID

NCT00486044

Run by

University of Wisconsin, Madison

People needed

103

Starts

2005-02-01

Expected to finish

2009-06-01

Last updated by the study team

2019-03-05

Who can join

Age: 35 and older, up to 69. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age 35 to 69
• Parent with Alzheimer's disease

You may not qualify if…

• Current use of cholesterol-lowering medication
• Active liver disease
• History of adverse reaction to statins
• Contraindication to lumbar puncture
• Elevated lab values (creatine kinase and creatinine)
• Use of medications known to interact with statins
• History of dementia
• Currently pregnant or planning to become pregnant
• Use of large quantities of grapefruit juice (more than 1 quart per day)
• Current involvement in another investigational drug study
• Contraindications to MRI (for MRI sub-study)
• Ethical contraindication to placebo (persons with high vascular risk)

Where it is running

• University of Wisconsin — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.